

Maidstone and 
Tunbridge Wells

NHS Trust

Ref: FOI/CAD/ID 3773

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

10 February 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to intra-vitreous vials or implants September – December 2016.

1. Within your trust how many intra-vitreous vials/implants have been used in the latest 4 months, if possible between September and December 2016 Please state the number of vials dispensed from your pharmacy in this period, if the number for wet AMD is not known, then regardless of reason for use.

2. Does your trust record the time taken from referral of a patient for treatment to the time for an injection or implant to be complete? If so what is the average waiting time for treatment with an injection of implant?

1. Please see the below table.

	Lucentis (ranibizumab) Injections	Avastin (bevacizumab) Injections	Eylea (aflibercept) Injections	Iluvien (Fluocinolone) Implants	Ozudex (Dexamethasone) Implants
Total Vials / Implants					
Vials for wet AMD	630	0	1266	0	Unknown
Vials for other conditions [DMO, RVO, CNV, Uveitis]	732	0	374	4	49 (total)

2. For WETAMD it is approximately 3 weeks from receipt of referral to treatment with either Lucentis (ranibizumab) Injections or Eylea (aflibercept) Injections. Ozurdex is approximately 4 weeks as is Iluvien. Avastin is given as per clinical indication.